To the Editor The review by Dr Wells and colleagues1 on the treatment of venous thromboembolism requires some clarifications. Table 1 in the article summarized new oral anticoagulants as treatment options for venous thromboembolism. However, only rivaroxaban is currently approved in both the United States and Europe, dabigatran was recently approved by the US Food and Drug Administration (FDA), and apixaban awaits approval by both the FDA and the European Medicines Agency.
Bikdeli B. Therapies for Venous Thromboembolism. JAMA. 2014;311(24):2543. doi:10.1001/jama.2014.6114